Lisa Lorraine Reyes Muñoz, GeneCell International’s Physicians Relations Manager, Launches Cord Blood Educational Meetings for General Public on Cord Blood Stem Cells
GeneCell International’s Physician’s Relations Manager Launches Cord Blood Educational Meetings to Increase Awareness within South Florida's Expecting Parent Community
Miami, Florida (PRWEB) July 17, 2013
Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relations Manager announced today her contribution to educating South Florida’s expecting parents to advance the awareness in the community. Expecting parents in Miami are encouraged to attend these meetings to learning more about this medical advancement.
Ms. Reyes Muñoz joined GeneCell International as a Physician Relations Manager, fluent in Spanish, with a science and pharmacology background. Reyes Muñoz has been interviewed by several Spanish networks including “Capsulas del Exito” and Preguntale a su Doctor, a weekly segment of GenTV (WGEN), in an effort to promote the awareness of cord blood preservation and its future potentials.
"What is most rewarding is to be able to apprise expecting parents and their families on the current and future treatments of these stem cells as well as explain the controversial differences about them," said Lisa Lorraine Reyes Muñoz.
Umbilical cord blood preservation is a process by which blood is collected from the umbilical cord of a newborn baby and is stored cryogenically in a specially-designated bank. According to the National Marrow Donor Program, cord blood contains cells that can be transfused to a patient to treat various diseases, including lymphoma and leukemia. The list of illnesses that can be treated with cord blood continues to grow.
"A person’s blood stem cell type is inherited, which means a patient is more likely to find a matched donor from within their own ethnic group," said GeneCell’s Director of Operations, Jose Cirino. "More than half of cord blood donations and privately banked cord blood in the United States are from Caucasians while minorities remain underrepresented. By increasing the awareness of cord blood advantages among minorities, there is a potential for increased access to therapies for more people."
Cord blood can be used to treat the child from whom the blood was collected as well as some first-degree relatives who are a close genetic match, such as family members. Cord blood banking is regulated by the U.S. Food & Drug Administration and each year more and more parents choose to save their children’s cord blood should the medical need arise.
GeneCell International specializes in the collection, transport, processing and cryogenic storage of adult stem cells from various sources including; umbilical cord blood, cord tissue segment, dental pulp (teeth) and adipose tissue (fat) that can later be used to treat a variety of diseases. The laboratory is also involved in scientific research and development with a range of stem cells from various adult tissues.
Alongside its commitment to educating the public on the benefits of cord blood preservation, GeneCell is committed to being on the forefront of stem cell research. GeneCell International is the only Cord Blood. Cord Tissue, Dental Pulp and Adipose Tissue Processing and Cryogenic Storage Laboratory to offer this cutting-edge, “regenerative medicine” technology in Miami, Florida.
GeneCell International, LLC is a trusted provider in the collection, processing and storage of adult stem cells from various sources which have the potential to treat a variety of diseases and disorders. Headquartered in Miami, Florida with local offices in Central Florida and international offices in Colombia, Costa Rica, Dominican Republic, Honduras, India, Peru, Puerto Rico and Venezuela, GeneCell operates state of the art laboratories and storage facilities for thousands of clients. For more information and to learn more about cord blood banking, dental pulp or other GeneCell services, please visit our website at http://www.GeneCell.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10916229.htm